APO Research
Talk to an analyst

APO RESEARCH · REPORT

Penpulimab Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Penpulimab Injection Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchPenpulimab Injection Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Penpulimab Injection Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Penpulimab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032171 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Penpulimab Injection Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Penpulimab Injection Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Penpulimab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Penpulimab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Penpulimab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Penpulimab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Penpulimab Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Penpulimab Injection market include Akeso, Inc. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Penpulimab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Penpulimab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Penpulimab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Penpulimab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Penpulimab Injection Segment by Company

Akeso, Inc

Penpulimab Injection Segment by Type

100mg (10mL)/Bottle

Other

Penpulimab Injection Segment by Application

Lymphoma

Liver Cancer

Lung Cancer

Nasopharyngeal Carcinoma

Gastric Cancer

Penpulimab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Penpulimab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Penpulimab Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Penpulimab Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Penpulimab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Penpulimab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Penpulimab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Penpulimab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Penpulimab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Penpulimab Injection industry.

Chapter 3: Detailed analysis of Penpulimab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Penpulimab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Penpulimab Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Penpulimab Injection Industry Trends Table 2. Penpulimab Injection Industry Drivers Table 3. Penpulimab Injection Industry Opportunities and Challenges Table 4. Penpulimab Injection Industry Restraints Table 5. Global Penpulimab Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Penpulimab Injection Revenue Share by Company (2021-2026) Table 7. Global Penpulimab Injection Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Penpulimab Injection Sales Volume Share by Company (2021-2026) Table 9. Global Penpulimab Injection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Penpulimab Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Penpulimab Injection Key Company Manufacturing Base & Headquarters Table 12. Global Penpulimab Injection Company, Product Type & Application Table 13. Global Penpulimab Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Penpulimab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 100mg (10mL)/Bottle Table 18. Significant Companies of Other Table 19. Global Penpulimab Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Penpulimab Injection Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Penpulimab Injection Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Penpulimab Injection Sales Volume Share by Type (2021-2026) Table 23. Global Penpulimab Injection Sales Volume Share by Type (2027-2032) Table 24. Global Penpulimab Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Penpulimab Injection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Penpulimab Injection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Penpulimab Injection Sales Value Share by Type (2021-2026) Table 28. Global Penpulimab Injection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Lymphoma Table 30. Significant Companies of Liver Cancer Table 31. Significant Companies of Lung Cancer Table 32. Significant Companies of Nasopharyngeal Carcinoma Table 33. Significant Companies of Gastric Cancer Table 34. Global Penpulimab Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Penpulimab Injection Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Penpulimab Injection Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Penpulimab Injection Sales Volume Share by Application (2021-2026) Table 38. Global Penpulimab Injection Sales Volume Share by Application (2027-2032) Table 39. Global Penpulimab Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Penpulimab Injection Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Penpulimab Injection Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Penpulimab Injection Sales Value Share by Application (2021-2026) Table 43. Global Penpulimab Injection Sales Value Share by Application (2027-2032) Table 44. Global Penpulimab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Penpulimab Injection Sales by Region (2021-2026) & (K Units) Table 46. Global Penpulimab Injection Sales Market Share by Region (2021-2026) Table 47. Global Penpulimab Injection Sales by Region (2027-2032) & (K Units) Table 48. Global Penpulimab Injection Sales Market Share by Region (2027-2032) Table 49. Global Penpulimab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Penpulimab Injection Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Penpulimab Injection Sales Value Share by Region (2021-2026) Table 52. Global Penpulimab Injection Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Penpulimab Injection Sales Value Share by Region (2027-2032) Table 54. Global Penpulimab Injection Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Penpulimab Injection Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Penpulimab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Penpulimab Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Penpulimab Injection Sales by Country (2021-2026) & (K Units) Table 59. Global Penpulimab Injection Sales Market Share by Country (2021-2026) Table 60. Global Penpulimab Injection Sales by Country (2027-2032) & (K Units) Table 61. Global Penpulimab Injection Sales Market Share by Country (2027-2032) Table 62. Global Penpulimab Injection Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Penpulimab Injection Sales Value Market Share by Country (2021-2026) Table 64. Global Penpulimab Injection Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Penpulimab Injection Sales Value Market Share by Country (2027-2032) Table 66. Akeso, Inc Company Information Table 67. Akeso, Inc Business Overview Table 68. Akeso, Inc Penpulimab Injection Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Akeso, Inc Penpulimab Injection Product Portfolio Table 70. Akeso, Inc Recent Development Table 71. Key Raw Materials Table 72. Raw Materials Key Suppliers Table 73. Penpulimab Injection Distributors List Table 74. Penpulimab Injection Customers List Table 75. Research Programs/Design for This Report Table 76. Authors List of This Report Table 77. Secondary Sources Table 78. Primary Sources List of Figures Figure 1. Penpulimab Injection Product Image Figure 2. Global Penpulimab Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Penpulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Penpulimab Injection Sales (2021-2032) & (K Units) Figure 5. Global Penpulimab Injection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Penpulimab Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 100mg (10mL)/Bottle Image Figure 10. Other Image Figure 11. Global Penpulimab Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Penpulimab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Penpulimab Injection Sales Volume Share by Type (2021-2032) Figure 14. Global Penpulimab Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Penpulimab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Penpulimab Injection Sales Value Share by Type (2021-2032) Figure 17. Lymphoma Image Figure 18. Liver Cancer Image Figure 19. Lung Cancer Image Figure 20. Nasopharyngeal Carcinoma Image Figure 21. Gastric Cancer Image Figure 22. Global Penpulimab Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Penpulimab Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Penpulimab Injection Sales Volume Share by Application (2021-2032) Figure 25. Global Penpulimab Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Penpulimab Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Penpulimab Injection Sales Value Share by Application (2021-2032) Figure 28. Global Penpulimab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Penpulimab Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Penpulimab Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Penpulimab Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Penpulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 33. North America Penpulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Penpulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Penpulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Penpulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Penpulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Penpulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 39. South America Penpulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Penpulimab Injection Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Penpulimab Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Penpulimab Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Penpulimab Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Penpulimab Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Penpulimab Injection Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Penpulimab Injection Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg (10mL)/Bottle
  • Other
Applications
  • Lymphoma
  • Liver Cancer
  • Lung Cancer
  • Nasopharyngeal Carcinoma
  • Gastric Cancer
Companies covered
  • Akeso, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Penpulimab Injection Sales Value (2021-2032)
  4. 1.2.2 Global Penpulimab Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Penpulimab Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Penpulimab Injection Market Dynamics
  1. 2.1 Penpulimab Injection Industry Trends
  2. 2.2 Penpulimab Injection Industry Drivers
  3. 2.3 Penpulimab Injection Industry Opportunities and Challenges
  4. 2.4 Penpulimab Injection Industry Restraints
3 Penpulimab Injection Market by Company
  1. 3.1 Global Penpulimab Injection Company Revenue Ranking in 2025
  2. 3.2 Global Penpulimab Injection Revenue by Company (2021-2026)
  3. 3.3 Global Penpulimab Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Penpulimab Injection Average Price by Company (2021-2026)
  5. 3.5 Global Penpulimab Injection Company Ranking (2024-2026)
  6. 3.6 Global Penpulimab Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Penpulimab Injection Company Product Type and Application
  8. 3.8 Global Penpulimab Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Penpulimab Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Penpulimab Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Penpulimab Injection Market by Type
  1. 4.1 Penpulimab Injection Type Introduction
  2. 4.1.1 100mg (10mL)/Bottle
  3. 4.1.2 Other
  4. 4.2 Global Penpulimab Injection Sales Volume by Type
  5. 4.2.1 Global Penpulimab Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Penpulimab Injection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Penpulimab Injection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Penpulimab Injection Sales Value by Type
  9. 4.3.1 Global Penpulimab Injection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Penpulimab Injection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Penpulimab Injection Sales Value Share by Type (2021-2032)
5 Penpulimab Injection Market by Application
  1. 5.1 Penpulimab Injection Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Liver Cancer
  4. 5.1.3 Lung Cancer
  5. 5.1.4 Nasopharyngeal Carcinoma
  6. 5.1.5 Gastric Cancer
  7. 5.2 Global Penpulimab Injection Sales Volume by Application
  8. 5.2.1 Global Penpulimab Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Penpulimab Injection Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Penpulimab Injection Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Penpulimab Injection Sales Value by Application
  12. 5.3.1 Global Penpulimab Injection Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Penpulimab Injection Sales Value by Application (2021-2032)
  14. 5.3.3 Global Penpulimab Injection Sales Value Share by Application (2021-2032)
6 Penpulimab Injection Regional Sales and Value Analysis
  1. 6.1 Global Penpulimab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Penpulimab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Penpulimab Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Penpulimab Injection Sales by Region (2027-2032)
  5. 6.3 Global Penpulimab Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Penpulimab Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Penpulimab Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Penpulimab Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Penpulimab Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Penpulimab Injection Sales Value (2021-2032)
  12. 6.6.2 North America Penpulimab Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Penpulimab Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Penpulimab Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Penpulimab Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Penpulimab Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Penpulimab Injection Sales Value (2021-2032)
  21. 6.9.2 South America Penpulimab Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Penpulimab Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Penpulimab Injection Sales Value Share by Country, 2025 VS 2032
7 Penpulimab Injection Country-level Sales and Value Analysis
  1. 7.1 Global Penpulimab Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Penpulimab Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Penpulimab Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Penpulimab Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Penpulimab Injection Sales by Country (2027-2032)
  6. 7.4 Global Penpulimab Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Penpulimab Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Penpulimab Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Penpulimab Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Penpulimab Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Penpulimab Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Penpulimab Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Penpulimab Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Penpulimab Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Penpulimab Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Penpulimab Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Penpulimab Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Penpulimab Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Penpulimab Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Penpulimab Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Penpulimab Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Penpulimab Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Penpulimab Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Penpulimab Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Penpulimab Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Penpulimab Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Penpulimab Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Penpulimab Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Penpulimab Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Penpulimab Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Penpulimab Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Penpulimab Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Penpulimab Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Penpulimab Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Penpulimab Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Penpulimab Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Penpulimab Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Penpulimab Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Akeso, Inc
  2. 8.1.1 Akeso, Inc Company Information
  3. 8.1.2 Akeso, Inc Business Overview
  4. 8.1.3 Akeso, Inc Penpulimab Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Akeso, Inc Penpulimab Injection Product Portfolio
  6. 8.1.5 Akeso, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Penpulimab Injection Value Chain Analysis
  2. 9.1.1 Penpulimab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Penpulimab Injection Sales Mode & Process
  6. 9.2 Penpulimab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Penpulimab Injection Distributors
  9. 9.2.3 Penpulimab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst